Company / R&D per Share
Biohaven Ltd. R&D per Share History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$8.72
FY2024
5-year range
$2.50 / $9.77
FY2020-FY2024
Trend
+66.4%
vs FY2023
Sector context
#19 of 208
Health Care
What the data says
Among 208 Health Care companies, Biohaven Ltd. is in the top 9% for r&d per share. Declined from $9.77 to $8.72 over the past 2 years.
Based on SEC 10-K filings.
8.72 in FY2024 with a 3-year CAGR of +23.7%. Top quartile in the Health Care sector.
Declined from $9.77 to $8.72 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +23.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 208This company $8.72 Sector average $12.19
▼
-28.5% below sector average
Key checks
Key Insights
- In FY2024, r&d per share increased 66.4% year-over-year.
- Ranks #19 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $8.72 | +66.4% |
| FY2023 | $5.24 | -46.3% |
| FY2022 | $9.77 | +111.9% |
| FY2021 | $4.61 | +84.3% |
| FY2020 | $2.50 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026